SNS-032 (Synonyms: BMS-387032)

Name: SNS-032
Brand: MedChemExpress
SKU: HY-10008
Rating: 5.0 (11 reviews)

Cat. No.: HY-10008 Purity: 99.91%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC₅₀s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect.

For research use only. We do not sell to patients.

CAS No. : 345627-80-7

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

Other Forms of SNS-032:

SNS-032 (Standard) Get quote

11 Publications Citing Use of MCE SNS-032

Others

In Vivo Efficacy Study

: SNS-032 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 5;15(1):10594. [Abstract]; Hut78 cells were pre-exposed to SNS-032 (10 μM; 2 h) or PHA-767491 followed by treatment with 23 (GT-02897). Then CDK9 protein was analyzed by Western blot.

: SNS-032 purchased from MedChemExpress. Usage Cited in: J Med Chem. 2025 Oct 23;68(20):21172-21186. [Abstract]; Mechanistic investigation of CDK9 degradation induced by dCDK9-202 in the TC-71 cell line. Cells were pretreated 2 h with CDK9 inhibitor 6 (SNS032, 10 μM), thalidomide (10 μM), (R)-MG132 (5 μM), and MLN4924 (2 μM) followed by 4 h treatment with dCDK9-202 at 20 nM concentration.

: SNS-032 purchased from MedChemExpress. Usage Cited in: J Med Chem. 2025 Oct 23;68(20):21172-21186. [Abstract]; RNA-seq analysis of TC-71 cells after treatment with dCDK9-202 (10 nM, 8 h) and SNS032 (10 nM, 8 h).

: SNS-032 purchased from MedChemExpress. Usage Cited in: J Med Chem. 2025 Oct 23;68(20):21172-21186. [Abstract]; Changes in tumor volume during dCDK9-202, 6 (SNS032), or 10 (THAL-SNS032) treatments (10 mg/kg, i.v., qod).

: SNS-032 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Feb 9;34(6):108736. [Abstract]; Lung myeloid-derived suppressor cells (MDSCs) were isolated from 8-10 week old C57Bl/6 mice. Cells were then treated with lipopolysaccharide (LPS) ± cardiolipin (CL), with controls provided by either a CDK-9 inhibitor (SNS-032: 10 nM) or a vector (Veh). Immunoprecipitation assays were performed to detect phosphorylation levels at the S112 site of PPARγ. Total PPARγ levels served as input controls.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC₅₀s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect^[1].

IC₅₀ & Target^[1]

CDK9

4 nM (IC₅₀)

CDK2

38 nM (IC₅₀)

CDK7

62 nM (IC₅₀)

CDK1

480 nM (IC₅₀)

CDK4

925 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.095 μM Compound: 21	Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay	[PMID: 15027863]
A2780	IC₅₀	95 nM Compound: 21	Inhibition of human A2780 cell proliferation Inhibition of human A2780 cell proliferation	[PMID: 15027863]
CWR22R	IC₅₀	0.384 μM Compound: 8; SNS032	Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability measured after 5 days by CellTiter-Glo assay Antiproliferative activity against human 22Rv1 cells assessed as reduction in cell viability measured after 5 days by CellTiter-Glo assay	[PMID: 35925880]
HCT-116	IC₅₀	0.458 μM Compound: 1, SNS-032	Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay Inhibition of CDK9 in human HCT116 cells assessed as phosphor-ser2 level of RNA polymerase 2 after 16 hrs by high content cellular assay	[PMID: 18842409]
HCT-116	IC₅₀	0.55 μM Compound: 1, SNS-032, BMS-387032	Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay Inhibition of CDK9-mediated RNA pol 2 phosphorylation at ser2 in human HCT116 cells after 16 hrs by HCS assay	[PMID: 18926699]
HCT-116	IC₅₀	0.7 μM Compound: BMS-387032	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 30197029]
MCF7	IC₅₀	1 μM Compound: BMS-387032	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30197029]
MOLT-4	IC₅₀	173 nM Compound: 13; SNS-032	Antiproliferative activity against human MOLT4 cells incubated for 72 hrs by cell titer glo assay Antiproliferative activity against human MOLT4 cells incubated for 72 hrs by cell titer glo assay	[PMID: 32866383]
RPMI-8226	IC₅₀	111 nM Compound: Chemical probe: SNS-032	Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of fetal bovine serum by MTT assay	[PMID: 19169685]
RPMI-8226	IC₅₀	148 nM Compound: Chemical probe: SNS-032	Antiproliferative activity against human RPMI-8226 cells incubated for 16 hrs by MTT assay Antiproliferative activity against human RPMI-8226 cells incubated for 16 hrs by MTT assay	[PMID: 19169685]
RPMI-8226	IC₅₀	79 nM Compound: Chemical probe: SNS-032	Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay Antiproliferative activity against human RPMI-8226 in presence of human serum by MTT assay	[PMID: 19169685]
Sf9	IC₅₀	21 nM Compound: SNS032	Inhibition of recombinant human full-length N-terminal GST-tagged CDK2/cyclinA1 expressed in baculovirus infected Sf9 insect cells using FRET-labeled Ser/Thr 12 as substrate measured after 1 hr by Z'-lyte assay Inhibition of recombinant human full-length N-terminal GST-tagged CDK2/cyclinA1 expressed in baculovirus infected Sf9 insect cells using FRET-labeled Ser/Thr 12 as substrate measured after 1 hr by Z'-lyte assay	[PMID: 32502343]
T-cell	IC₅₀	4 nM Compound: 15; SNS-033	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 35485642]
T-cell	IC₅₀	4 nM Compound: Chemical probe: SNS-032	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 19169685]

In Vitro

SNS-032 has low sensitivity to CDK1 and CDK4 with IC₅₀ of 480 nM and 925 nM, respectively. SNS-032 effectively kills chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history. Compared with flavopiridol and roscovitine, SNS-032 is more potent, both in inhibition of RNA synthesis and at induction of apoptosis. SNS-032 activity is readily reversible; removal of SNS-032 reactivates RNA polymerase II, which led to resynthesis of Mcl-1 and cell survival^[1]. SNS-032 inhibits three dimensional capillary network formations of endothelial cells. SNS-032 completely prevents U87MG cell-mediated capillary formation of HUVECs. In addition, SNS-032 significantly prevents the production of VEGF in both cell lines, SNS-032 prevents in vitro angiogenesis, and this action is attributable to blocking of VEGF. Preclinical studies have shown that SNS-032 induces cell cycle arrest and apoptosis across multiple cell lines^[2]. SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9. SNS-032 activity is unaffected by human serum^[3]. SNS-032 induces a dose-dependent increase in annexin V staining and caspase-3 activation. At the molecular level, SNS-032 induces a marked dephosphorylation of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibits the expression of CDK2 and CDK9 and dephosphorylated CDK7^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SNS-032 (15 mg/kg, i.p.) inhibits both xenografted BaF3-T674I cells and KBM5-T315I cells in vivo. SNS-032 abrogates the growth of tumors transplanted in nude mice with downregulation of T674I PDGFRα and T315I-Bcr-Abl^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

380.53

Formula

C₁₇H₂₄N₄O₂S₂

CAS No.

345627-80-7

Appearance

Solid

Color

White to light yellow

SMILES

CC(C)(C1=CN=C(CSC2=CN=C(NC(C3CCNCC3)=O)S2)O1)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (131.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6279 mL	13.1396 mL	26.2791 mL
5 mM	0.5256 mL	2.6279 mL	5.2558 mL
10 mM	0.2628 mL	1.3140 mL	2.6279 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (26.28 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 25 mg/mL (65.70 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (246 KB) HNMR (274 KB) RP-HPLC (241 KB) LCMS (101 KB)

Handling Instructions (2659 KB)

References

[1]. Chen R, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. [Content Brief]

[2]. Ali MA, et al. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 2007 May;9(5):370-81. [Content Brief]

[3]. Conroy A, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32. [Content Brief]

[4]. Wu Y, et al. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.Clin Cancer Res. 2012 Apr 1;18(7):1966-78. Epub 2012 Mar 23. [Content Brief]

[5]. Walsby E, et al. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells. Leukemia. 2011 Mar;25(3):411-9. Epub 2011 Jan 7. [Content Brief]

Cell Assay ^[2]	Cell Titer-Glo (CTG) luminescent assay is performed to measure the growth curves of both HUVECs and U87MG cells. U87MG cells and HUVECs (2×10³ cells/well) are seeded in a 96-well microplate in a final volume of 100 mL. After 24 hours, cells are treated with various doses of SNS-032 (0-0.5 mM) for 24, 48, or 72 hours. After completion of the treatment, 100 mL of CTG solution is added to each well and incubated for 20 minutes at room temperature in the dark. Lysate (50 mL) is transferred to a 96-well white plate, and luminescence is measured by POLARstar OPTIMA. Percent cell growth is calculated by considering 100% growth at the time of SNS-032 addition. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Nude nu/nu BALB/c mice are housed in barrier facilities with a 12-hour light-dark cycle, with food and water available ad libitum. A mixture of 1×10⁷ of BaF3-T674I cells with Matrigel or KBM5-T315I cells (3×10⁷) are inoculated subcutaneously on the flanks of 4- to 6-week-old male nude mice. Tumors are measured every other day with use of calipers. Tumor volumes are calculated by the following formula: a²×b×0.4, where a is the smallest diameter and b is the diameter perpendicular to a. Four days after subcutaneous inoculation, when tumors are palpable (appr 100 mm³), mice are randomized to receive treatment with vehicle (tissue culture medium containing DMSO 0.1% v/v) or SNS-032 (15 mg/kg injected intraperitoneally every 2 days) for about 2 weeks. SNS-032 is dissolved in tissue culture grade DMSO before dilution. The body weight, feeding behavior, and motor activity of each animal are monitored as indicators of general health. The animals are then euthanized, and tumor xenografts are immediately removed, weighed, stored, and fixed. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Chen R, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. [Content Brief] [2]. Ali MA, et al. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 2007 May;9(5):370-81. [Content Brief] [3]. Conroy A, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64(4):723-32. [Content Brief] [4]. Wu Y, et al. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.Clin Cancer Res. 2012 Apr 1;18(7):1966-78. Epub 2012 Mar 23. [Content Brief] [5]. Walsby E, et al. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells. Leukemia. 2011 Mar;25(3):411-9. Epub 2011 Jan 7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6279 mL	13.1396 mL	26.2791 mL	65.6978 mL
	5 mM	0.5256 mL	2.6279 mL	5.2558 mL	13.1396 mL
	10 mM	0.2628 mL	1.3140 mL	2.6279 mL	6.5698 mL
	15 mM	0.1752 mL	0.8760 mL	1.7519 mL	4.3799 mL
	20 mM	0.1314 mL	0.6570 mL	1.3140 mL	3.2849 mL
	25 mM	0.1051 mL	0.5256 mL	1.0512 mL	2.6279 mL
	30 mM	0.0876 mL	0.4380 mL	0.8760 mL	2.1899 mL
	40 mM	0.0657 mL	0.3285 mL	0.6570 mL	1.6424 mL
	50 mM	0.0526 mL	0.2628 mL	0.5256 mL	1.3140 mL
	60 mM	0.0438 mL	0.2190 mL	0.4380 mL	1.0950 mL
	80 mM	0.0328 mL	0.1642 mL	0.3285 mL	0.8212 mL
	100 mM	0.0263 mL	0.1314 mL	0.2628 mL	0.6570 mL

SNS-032 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SNS-032345627-80-7BMS-387032SNS032SNS 032BMS387032BMS 387032CDKApoptosisCyclin dependent kinaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

SNS-032 (Synonyms: BMS-387032)

Customer Review

Other Forms of SNS-032:

SNS-032 Related Antibodies

11 Publications Citing Use of MCE SNS-032

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All CDK Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

SNS-032 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

SNS-032 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report